Respivert Limited

Chroma Therapeutics Limited

University of Leicester

Simon Christopher Hirst

Stuart Thomas Onions

Jonathan Gareth Williams

Kazuhiro Ito

John King-Underwood

Peter Strong

Peter John Murray

Catherine Elisabeth Charron

David Michel Adrien Taddei

William Garth Rapeport

David Festus Charles Moffat

Stephen John Davies

Michael Hugh Charlton

Fritz-Frieder Frickel

David Charles Festus Moffat

Daniel Hamza

Peter Andrew

Rana Lonnen

Mark William Davies

Jonathon Gareth Williams

Catherine Elizabeth Charron

There are provided inter alia compounds of formula (I) wherein R, R, R, Rand Rare as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections. 

Pyrrole derivatives

There are provided inter alia compounds of formula (I) wherein R, Ar, L, X, Rand Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.

P38 MAP kinase inhibitors

The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

p38 MAP kinase inhibitors

The invention provides a compound which is (a) an amino acid derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R, R, L, Het, A, x, y and W are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90. 

Adenine derivative as inhibitors of HSP90 for the treatment of cancer

Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: wherein Ris hydrogen or optionally substituted (C-C)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L-Y&#x2014;(CH)&#x2014;, wherein: z is 0 or 1; R is a radical of formula (X) or (Y) Ris a carboxylic acid group (&#x2014;COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; Ris hydrogen, or optionally substituted C-Calkyl, C-Ccycloalkyl, aryl or heteroaryl or &#x2014;(C&#x2550;O)R, &#x2014;(C&#x2550;O)OR, or &#x2014;(C&#x2550;O)NRwherein Ris hydrogen or optionally substituted (C-C)alkyl; Yis a bond, &#x2014;(C&#x2550;O)&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;C(&#x2550;O)O&#x2014;, &#x2014;OC(&#x2550;O)&#x2014;, &#x2014;(C&#x2550;O)NR&#x2014;, &#x2014;NR(C&#x2550;O)&#x2014;, &#x2014;S(O)NR&#x2014;, &#x2014;NRS(O)&#x2014;, or &#x2014;NR(C&#x2550;O)NR&#x2014;, wherein Rand Rare independently hydrogen or optionally substituted (C-C)alkyl, Lis a divalent linker radical of formula -(Alk)(Q)(Alk)- wherein m, n, p, Q, Alkand Alkare as defined in the claims.

Inhibitors of IKK-beta serine-threonine protein kinase

Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein Ris hydrogen or optionally substituted (C-C)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula RRCHNH&#x2014;Y-L-X&#x2014;(CH)&#x2014; wherein: z is 0 or 1; R1 is a carboxylic acid group (&#x2014;COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, &#x2014;C(&#x2550;O)&#x2014;, &#x2014;S(&#x2550;P)2-, &#x2014;C(&#x2550;O)O&#x2014;, &#x2014;C(&#x2550;O)NR3-, &#x2014;C(&#x2550;S)&#x2014;NR, &#x2014;C(&#x2550;NH)&#x2014;NRor &#x2014;S(&#x2550;O)NR&#x2014; wherein Ris hydrogen or optionally substituted C-Calkyl; L is a divalent linker radical of formula -(Alk)(Q)(Alk)- wherein m, n, p, Q, AIkand AIkare as defined in the claims. 

IKK-beta serine-threonine protein kinase inhibitors

Growing community of inventors

Nottingham, United Kingdom

Simon Christopher Hirst